

1/8

FIG.1.





FIG.2.



2/8

FIG. 3.

09/4/98

CLINICAL PERFORMANCE OF FDP
NORMAL vs FIVE TYPES OF CANCER(n=50)




FIG. 4.

BREAST CANCER
FDP vs CA 15-3






FIG. 5.COLON CANCER
FDP vs CA 19-9 (n=22)**FIG. 6.**COLON CANCER
FDP vs CEA (n=28)

09/4/2014

PCT/US98/11162

WO 98/55872

4/8

FIG. 7.

LUNG CANCER
FDP vs CEA






FIG. 8.

OVARY CANCER
FDP vs CA 125



SUBSTITUTE SHEET (RULE 26)

5/8

FIG. 9.PROSTATE CANCER
FDP vs PSA

6/8

FIG. 10A





FIG. 10B

GOAT α MOUSE IgG - HRP

7/8

FIG. 10C





FIG. 10D



09/424740

8/8

FIG. 11a.




FIG. 11b.




FIG. 11c.




Figure 11. Selectivity of the Onochek assay: (A) noncompetitive inhibition by fibrinogen fragment D; (B) double reciprocal plot for fibrinogen; and (C) double reciprocal plot for fibrinogen fragment E.